Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein

Science

Volumn 349, Issue 6248, 2015, Pages

  Goedert, Michel ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; PRION PROTEIN; TAU PROTEIN; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; PRION; PRNP PROTEIN, HUMAN; SNCA PROTEIN, HUMAN;

BRAIN; GENE EXPRESSION; MUTATION; NERVOUS SYSTEM DISORDER; NEUROLOGY; PATHOLOGY; PHENOTYPE; PROTEIN;

ALZHEIMER DISEASE; GENE MUTATION; HUMAN; NERVE DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN SYNTHESIS; REVIEW; BRAIN; GENETICS; LEWY BODY; METABOLISM; MUTATION; PATHOLOGY; PRION; PRION DISEASE;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BRAIN; HUMANS; LEWY BODIES; MUTATION; PARKINSON DISEASE; PRION DISEASES; PRIONS; TAU PROTEINS;

EID: 84939506533     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1255555     Document Type: Review

References (139)

1. M. Goedert, M. G. Spillantini, A century of Alzheimer's disease. Science 314, 777-781 (2006). doi: 10.1126/science.1132814; pmid: 17082447
2. M. Goedert, M. G. Spillantini, K. Del Tredici, H. Braak, 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13-24 (2013). doi: 10.1038/nrneurol.2012.242; pmid: 23183883
3. A. Goate et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease, Nature 349, 704-706 (1991).
4. P. Poorkaj et al., Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815-825 (1998). doi: 10.1002/ana.410430617; pmid: 9629852
5. M. Hutton et al., Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705 (1998). doi: 10.1038/31508; pmid: 9641683
6. M. G. Spillantini et al., Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U.S.A. 95, 7737-7741 (1998). doi: 10.1073/pnas.95.13.7737; pmid: 9636220
7. M. H. Polymeropoulos et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997). doi: 10.1126/science.276.5321.2045; pmid: 9197268
8. M. Jucker, L. C. Walker, Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45-51 (2013). doi: 10.1038/nature12481; pmid: 24005412
9. M. Goedert, B. Falcon, F. Clavaguera, M. Tolnay, Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr. Neurol. Neurosci. Rep. 14, 495 (2014). doi: 10.1007/s11910-014-0495-z; pmid: 25218483
10. D. Eisenberg, M. Jucker, The amyloid state of proteins in human diseases. Cell 148, 1188-1203 (2012). doi: 10.1016/j.cell.2012.02.022; pmid: 22424229
11. R. Nelson et al., Structure of the cross-β spine of amyloid-like fibrils. Nature 435, 773-778 (2005). doi: 10.1038/nature03680; pmid: 15944695
12. M. R. Sawaya et al., Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature 447, 453-457 (2007). doi: 10.1038/nature05695; pmid: 17468747
13. A. Laganowsky et al., Atomic view of a toxic amyloid small oligomer. Science 335, 1228-1231 (2012). doi: 10.1126/science.1213151; pmid: 22403391
14. A. T. Petkova et al., Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307, 262-265 (2005). doi: 10.1126/science.1105850; pmid: 15653506
15. P. Jenner et al., Parkinson's disease - The debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J. Parkinson's Dis. 3, 1 (2013).
16. K. Wakabayashi, M. Yoshimoto, S. Tsuji, H. Takahashi, Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249, 180-182 (1998). doi: 10.1016/S0304-3940(98)00407-8; pmid: 9682846
17. M. G. Spillantini et al., Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208 (1998). doi: 10.1016/S0304-3940(98)00504-7; pmid: 9726379
18. P. H. Tu et al., Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol. 44, 415-422 (1998). doi: 10.1002/ana.410440324; pmid: 9749615
19. M. I. Papp, J. E. Kahn, P. L. Lantos, Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 94, 79-100 (1989). doi: 10.1016/0022-510X(89)90219-0; pmid: 2559165
20. A. Fanciulli, G. K. Wenning, Multiple-system atrophy. N. Engl. J. Med. 372, 249-263 (2015). doi: 10.1056/NEJMra1311488; pmid: 25587949
21. K. Nakamura et al., Filamentous aggregations of phosphorylated α-synuclein in Schwann cells (Schwann cell cytoplasmic inclusions) in multiple system atrophy. Acta Neuropathol. Commun. 3, 29 (2015). doi: 10.1186/s40478-015-0208-0; pmid: 25990096
22. T. Alper, D. A. Haig, M. C. Clarke, The exceptionally small size of the scrapie agent. Biochem. Biophys. Res. Commun. 22, 278-284 (1966). doi: 10.1016/0006-291X(66)90478-5; pmid: 4957205
23. T. Alper, W. A. Cramp, D. A. Haig, M. C. Clarke, Does the agent of scrapie replicate without nucleic acid? Nature 214, 764-766 (1967). doi: 10.1038/214764a0; pmid: 4963878
24. D. C. Bolton, M. P. McKinley, S. B. Prusiner, Identification of a protein that purifies with the scrapie prion. Science 218, 1309-1311 (1982). doi: 10.1126/science.6815801; pmid: 6815801
25. S. B. Prusiner, Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982). doi: 10.1126/science.6801762; pmid: 6801762
26. M. S. Palmer, A. J. Dryden, J. T. Hughes, J. Collinge, Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352, 340-342 (1991). doi: 10.1038/352340a0; pmid: 1677164
27. D. Kaski et al., Variant CJD in an individual heterozygous for PRNP codon 129. Lancet 374, 2128 (2009). doi: 10.1016/S0140-6736(09)61568-3; pmid: 20109837
28. F. Owen et al., Insertion in prion protein gene in familial Creutzfeldt-Jakob disease. Lancet 333, 51-52 (1989). doi: 10.1016/S0140-6736(89)91713-3; pmid: 2563037
29. K. Hsiao et al., Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome. Nature 338, 342-345 (1989). doi: 10.1038/338342a0; pmid: 2564168
30. S. B. Prusiner, Prions. Proc. Natl. Acad. Sci. U.S.A. 95, 13363-13383 (1998). doi: 10.1073/pnas.95.23.13363; pmid: 9811807
31. W. Q. Zou et al., Variably protease-sensitive prionopathy: A new sporadic disease of the prion protein. Ann. Neurol. 68, 162-172 (2010). pmid: 20695009
32. H. Fraser, Neuronal spread of scrapie agent and targeting of lesions within the retino-tectal pathway. Nature 295, 149-150 (1982). doi: 10.1038/295149a0; pmid: 6173756
33. R. A. Bessen, R. F. Marsh, Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J. Virol. 66, 2096-2101 (1992). pmid: 1347795
34. M. Tanaka, S. R. Collins, B. H. Toyama, J. S. Weissman, The physical basis of how prion conformations determine strain phenotypes. Nature 442, 585-589 (2006). doi: 10.1038/nature04922; pmid: 16810177
35. D. Vilchez, I. Saez, A. Dillin, The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat. Commun. 5, 5659 (2014). doi: 10.1038/ncomms6659; pmid: 25482515
36. S. Mead et al., A novel protective prion protein variant that colocalizes with kuru exposure. N. Engl. J. Med. 361, 2056-2065 (2009). doi: 10.1056/NEJMoa0809716; pmid: 19923577
37. E. A. Asante et al., A naturally occurring variant of the human prion protein completely prevents prion disease. Nature 522, 478-481 (2015). doi: 10.1038/nature14510; pmid: 26061765
38. S. B. Prusiner et al., Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35, 349-358 (1983). doi: 10.1016/0092-8674(83)90168-X; pmid: 6418385
39. S. B. Prusiner, S. P. Cochran, M. P. Alpers, Transmission of scrapie in hamsters. J. Infect. Dis. 152, 971-978 (1985). doi: 10.1093/infdis/152.5.971; pmid: 3930630
40. G. A. H. Wells et al., Bovine spongiform encephalopathy: The effect of oral exposure dose on attack rate and incubation period in cattle. J. Gen. Virol. 88, 1363-1373 (2007). doi: 10.1099/vir.0.82421-0; pmid: 17374783
41. E. Zobeley, E. Flechsig, A. Cozzio, M. Enari, C. Weissmann, Infectivity of scrapie prions bound to a stainless steel surface. Mol. Med. 5, 240-243 (1999). pmid: 10448646
42. Y. S. Eisele et al., Induction of cerebral beta-amyloidosis: Intracerebral versus systemic Aβ inoculation. Proc. Natl. Acad. Sci. U.S.A. 106, 12926-12931 (2009). doi: 10.1073/pnas.0903200106; pmid: 19622727
43. S. K. Fritschi et al., Aβ seeds resist inactivation by formaldehyde. Acta Neuropathol. 128, 477-484 (2014). doi: 10.1007/s00401-014-1339-2; pmid: 25193240
44. M. Schweighauser et al., Formaldehyde-fixed brain tissue from spontaneously ill α-synuclein transgenic mice induces fatal α-synucleinopathy in transgenic hosts. Acta Neuropathol. 129, 157-159 (2015). doi: 10.1007/s00401-014-1360-5; pmid: 25367384
45. R. S. Hegde et al., Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402, 822-826 (1999). doi: 10.1038/45574; pmid: 10617204
46. A. F. Hill et al., Species-barrier-independent prion replication in apparently resistant species. Proc. Natl. Acad. Sci. U.S.A. 97, 10248-10253 (2000). doi: 10.1073/pnas.97.18.10248; pmid: 10963685
47. M. K. Sandberg et al., Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nat. Commun. 5, 4347 (2014). doi: 10.1038/ncomms5347; pmid: 25005024
48. J. A. Moreno et al., Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci. Transl. Med. 5, 206ra138 (2013). doi: 10.1126/scitranslmed.3006767; pmid: 24107777
49. J. Kang et al., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736 (1987). doi: 10.1038/325733a0; pmid: 2881207
50. C. L. Masters, D. J. Selkoe, Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006262 (2012). doi: 10.1101/cshperspect.a006262; pmid: 22675658
51. P. Lu et al., Three-dimensional structure of human γ-secretase. Nature 512, 166-170 (2014). doi: 10.1038/nature13567; pmid: 25043039
52. T. Xie et al., Crystal structure of the γ-secretase component nicastrin. Proc. Natl. Acad. Sci. U.S.A. 111, 13349-13354 (2014). doi: 10.1073/pnas.1414837111; pmid: 25197054
53. H. Acx et al., Signature amyloid β profiles are produced by different γ-secretase complexes. J. Biol. Chem. 289, 4346-4355 (2014). doi: 10.1074/jbc.M113.530907; pmid: 24338474
54. D. C. Gajdusek, C. J. Gibbs, M. Alpers, Experimental transmission of a Kuru-like syndrome to chimpanzees. Nature 209, 794-796 (1966). doi: 10.1038/209794a0; pmid: 5922150
55. J. Goudsmit et al., Evidence for and against the transmissibility of Alzheimer disease. Neurology 30, 945-950 (1980). doi: 10.1212/WNL.30.9.945; pmid: 6775247
56. H. F. Baker, R. M. Ridley, L. W. Duchen, T. J. Crow, C. J. Bruton, Evidence for the experimental transmission of cerebral β-amyloidosis to primates. Int. J. Exp. Pathol. 74, 441-454 (1993). pmid: 8217779
57. M. D. Kane et al., Evidence for seeding of β-amyloid by intracerebral infusion of Alzheimer brain extracts in β-amyloid precursor protein-transgenic mice. J. Neurosci. 20, 3606-3611 (2000). pmid: 10804202
58. M. Meyer-Luehmann et al., Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 1781-1784 (2006). doi: 10.1126/science.1131864; pmid: 16990547
59. Y. S. Eisele et al., Peripherally applied Abeta-containing inoculates induce cerebral β-amyloidosis. Science 330, 980-982 (2010). doi: 10.1126/science.1194516; pmid: 20966215
60. J. Stöhr et al., Purified and synthetic Alzheimer's amyloid β (Aβ) prions. Proc. Natl. Acad. Sci. U.S.A. 109, 11025-11030 (2012). doi: 10.1073/pnas.1206555109; pmid: 22711819
61. R. Morales, C. Duran-Aniotz, J. Castilla, L. D. Estrada, C. Soto, De novo induction of amyloid-β deposition in vivo. Mol. Psychiatry 17, 1347-1353 (2012). doi: 10.1038/mp.2011.120; pmid: 21968933
62. H. Braak, E. Braak, Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259 (1991). doi: 10.1007/BF00308809; pmid: 1759558
63. D. R. Thal, U. Rüb, M. Orantes, H. Braak, Phases of A β-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800 (2002). doi: 10.1212/WNL.58.12.1791; pmid: 12084879
64. H. Braak, K. Del Tredici, Neuroanatomy and pathology of sporadic Alzheimer's disease. Adv. Anat. Embryol. Cell Biol. 215, 1-162 (2015). doi: 10.1007/978-3-319-12679-1-1; pmid: 25920101
65. J. Stöhr et al., Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice. Proc. Natl. Acad. Sci. U.S.A. 111, 10329-10334 (2014). doi: 10.1073/pnas.1408968111; pmid: 24982137
66. J. C. Watts et al., Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proc. Natl. Acad. Sci. U.S.A. 111, 10323-10328 (2014). doi: 10.1073/pnas.1408900111; pmid: 24982139
67. P. T. Nelson et al., Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 71, 362-381 (2012). doi: 10.1097/NEN.0b013e31825018f7; pmid: 22487856
68. J. Lewis et al., Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491 (2001). doi: 10.1126/science.1058189; pmid: 11520987
69. S. H. Choi et al., A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515, 274-278 (2014). doi: 10.1038/nature13800; pmid: 25307057
70. E. D. Roberson et al., Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754 (2007). doi: 10.1126/science.1141736; pmid: 17478722
71. H. Stefansson et al., A common inversion under selection in Europeans. Nat. Genet. 37, 129-137 (2005). doi: 10.1038/ng1508; pmid: 15654335
72. G. U. Höglinger et al., Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699-705 (2011). doi: 10.1038/ng.859; pmid: 21685912
73. H. Braak, K. Del Tredici, The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 121, 171-181 (2011). doi: 10.1007/s00401-010-0789-4; pmid: 21170538
74. C. R. Jack Jr. et al., Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216 (2013). doi: 10.1016/S1474-4422(12)70291-0; pmid: 23332364
75. J. F. Crary et al., Primary age-related tauopathy (PART): A common pathology associated with human aging. Acta Neuropathol. 128, 755-766 (2014). doi: 10.1007/s00401-014-1349-0; pmid: 25348064
76. C. Duyckaerts et al., PART is part of Alzheimer disease. Acta Neuropathol. 129, 749-756 (2015). doi: 10.1007/s00401-015-1390-7; pmid: 25628035
77. Y. Saito et al., Staging of argyrophilic grains: An age-associated tauopathy. J. Neuropathol. Exp. Neurol. 63, 911-918 (2004). pmid: 15453090
78. A. C. McKee et al., The spectrum of disease in chronic traumatic encephalopathy. Brain 136, 43-64 (2013). doi: 10.1093/brain/aws307; pmid: 23208308
79. F. Clavaguera et al., Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11, 909-913 (2009). doi: 10.1038/ncb1901; pmid: 19503072
80. Z. Ahmed et al., A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: The pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 127, 667-683 (2014). doi: 10.1007/s00401-014-1254-6; pmid: 24531916
81. F. Clavaguera et al., Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. U.S.A. 110, 9535-9540 (2013). doi: 10.1073/pnas.1301175110; pmid: 23690619
82. L. Liu et al., Trans-synaptic spread of tau pathology in vivo. PLOS ONE 7, e31302 (2012). doi: 10.1371/journal.pone.0031302; pmid: 22312444
83. A. de Calignon et al., Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697 (2012). doi: 10.1016/j.neuron.2011.11.033; pmid: 22365544
84. F. Clavaguera et al., Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 127, 299-301 (2014). doi: 10.1007/s00401-013-1231-5; pmid: 24362441
85. D. W. Sanders et al., Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271-1288 (2014). doi: 10.1016/j.neuron.2014.04.047; pmid: 24857020
86. B. Falcon et al., Conformation determines the seeding potencies of native and recombinant Tau aggregates. J. Biol. Chem. 290, 1049-1065 (2015). doi: 10.1074/jbc.M114.589309; pmid: 25406315
87. S. Boluda et al., Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. Acta Neuropathol. 129, 221-237 (2015). doi: 10.1007/s00401-014-1373-0; pmid: 25534024
88. R. A. Crowther, M. Goedert, Abnormal tau-containing filaments in neurodegenerative diseases. J. Struct. Biol. 130, 271-279 (2000). doi: 10.1006/jsbi.2000.4270; pmid: 10940231
89. J. Zhou, E. D. Gennatas, J. H. Kramer, B. L. Miller, W. W. Seeley, Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 73, 1216-1227 (2012). doi: 10.1016/j.neuron.2012.03.004; pmid: 22445348
90. F. Roselli, P. Caroni, From intrinsic firing properties to selective neuronal vulnerability in neurodegenerative diseases. Neuron 85, 901-910 (2015). doi: 10.1016/j.neuron.2014.12.063; pmid: 25741719
91. B. Frost, R. L. Jacks, M. I. Diamond, Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845-12852 (2009). doi: 10.1074/jbc.M808759200; pmid: 19282288
92. T. Nonaka, S. T. Watanabe, T. Iwatsubo, M. Hasegawa, Seeded aggregation and toxicity of α-synuclein and tau: Cellular models of neurodegenerative diseases. J. Biol. Chem. 285, 34885-34898 (2010). doi: 10.1074/jbc.M110.148460; pmid: 20805224
93. J. T. Bendor, T. P. Logan, R. H. Edwards, The function of α-synuclein. Neuron 79, 1044-1066 (2013). doi: 10.1016/j.neuron.2013.09.004; pmid: 24050397
94. J. Burré, M. Sharma, T. C. Südhof, Definition of a molecular pathway mediating α-synuclein neurotoxicity. J. Neurosci. 35, 5221-5232 (2015). doi: 10.1523/JNEUROSCI.4650-14.2015; pmid: 25834048
95. K. C. Luk et al., Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. U.S.A. 106, 20051-20056 (2009). doi: 10.1073/pnas.0908005106; pmid: 19892735
96. H. Braak et al., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003). doi: 10.1016/S0197-4580(02)00065-9; pmid: 12498954
97. H. Braak, K. Del Tredici, Neuroanatomy and pathology of sporadic Parkinson's disease. Adv. Anat. Embryol. Cell Biol. 201, 1-119 (2009). pmid: 19230552
98. E. Svensson et al., Vagotomy and subsequent risk of Parkinson's disease. Ann. Neurol. 10.1002/ana24448 (2015). doi: 10.1002/ana24448
99. J. Y. Li et al., Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501-503 (2008). doi: 10.1038/nm1746; pmid: 18391963
100. J. H. Kordower, Y. Chu, R. A. Hauser, T. B. Freeman, C. W. Olanow, Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504-506 (2008). doi: 10.1038/nm1747; pmid: 18391962
101. C. W. Olanow, S. B. Prusiner, Is Parkinson's disease a prion disorder? Proc. Natl. Acad. Sci. U.S.A. 106, 12571-12572 (2009). doi: 10.1073/pnas.0906759106 pmid: 19666621
102. P. Desplats et al., Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc. Natl. Acad. Sci. U.S.A. 106, 13010-13015 (2009). doi: 10.1073/pnas.0903691106; pmid: 19651612
103. A. L. Mougenot et al., Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225-2228 (2012). doi: 10.1016/j.neurobiolaging.2011.06.022; pmid: 21813214
104. J. C. Watts et al., Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 110, 19555-19560 (2013). doi: 10.1073/pnas.1318268110; pmid: 24218576
105. A. N. Sacino et al., Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 111, 10732-10737 (2014). doi: 10.1073/pnas.1321785111; pmid: 25002524
106. S. Holmqvist et al., Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 128, 805-820 (2014). doi: 10.1007/s00401-014-1343-6; pmid: 25296989
107. W. Peelaerts et al., α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340-344 (2015). doi: 10.1038/nature14547; pmid: 26061766
108. K. C. Luk et al., Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953 (2012). doi: 10.1126/science.1227157; pmid: 23161999
109. M. Masuda-Suzukake et al., Prion-like spreading of pathological α-synuclein in brain. Brain 136, 1128-1138 (2013). doi: 10.1093/brain/awt037; pmid: 23466394
110. L. Bousset et al., Structural and functional characterization of two α-synuclein strains. Nat. Commun. 4, 2575 (2013). doi: 10.1038/ncomms3575; pmid: 24108358
111. J. L. Guo et al., Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103-117 (2013). doi: 10.1016/j.cell.2013.05.057; pmid: 23827677
112. I. Benilova, E. Karran, B. De Strooper, The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat. Neurosci. 15, 349-357 (2012). doi: 10.1038/nn.3028; pmid: 22286176
113. R. Sherrington et al., Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760 (1995). doi: 10.1038/375754a0; pmid:7596406
114. E. Levy-Lahad et al., Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977 (1995). doi: 10.1126/science.7638622; pmid: 7638622
115. B. Wang et al., γ-Secretase gene mutations in familial acne inversa. Science 330, 1065 (2010). doi: 10.1126/science.1196284; pmid: 20929727
116. T. Jonsson et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99 (2012). doi: 10.1038/nature11283; pmid: 22801501
117. E. H. Corder et al., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923 (1993). doi: 10.1126/science.8346443; pmid: 8346443
118. R. W. Mahley, Y. Huang, Apolipoprotein E sets the stage: Response to injury triggers neuropathology. Neuron 76, 871-885 (2012). doi: 10.1016/j.neuron.2012.11.020; pmid: 23217737
119. D. Harold et al., Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41, 1088-1093 (2009). doi: 10.1038/ng.440; pmid: 19734902
120. J. C. Lambert et al., Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41, 1094-1099 (2009). doi: 10.1038/ng.439; pmid: 19734903
121. T. Jonsson et al., Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107-116 (2013). doi: 10.1056/NEJMoa1211103; pmid: 23150908
122. R. Guerreiro et al., TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127 (2013). doi: 10.1056/NEJMoa1211851; pmid: 23150934
123. K. G. Mawuenyega et al., Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 330, 1774 (2010). doi: 10.1126/science.1197623; pmid: 21148344
124. R. Potter et al., Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci. Transl. Med. 5, 189ra77 (2013). doi: 10.1126/scitranslmed.3005615; pmid: 23761040
125. A. B. Singleton et al., α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003). doi: 10.1126/science.1090278; pmid: 14593171
126. A. P. Kiely et al., α-Synucleinopathy associated with G51D SNCA mutation: A link between Parkinson's disease and multiple system atrophy? Acta Neuropathol. 125, 753-769 (2013). doi: 10.1007/s00401-013-1096-7; pmid: 23404372
127. P. Pasanen et al., Novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging 35, 2180.e1-2180.e5 (2014). doi: 10.1016/j.neurobiolaging.2014.03.024; pmid: 24746362
128. C. Paisán-Ruíz et al., Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600 (2004). doi: 10.1016/j.neuron.2004.10.023; pmid: 15541308
129. A. Zimprich et al., Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607 (2004). doi: 10.1016/j.neuron.2004.11.005; pmid: 15541309
130. A. Gardet et al., LRRK2 is involved in the IFN-gamma response and host response to pathogens. J. Immunol. 185, 5577-5585 (2010). doi: 10.4049/jimmunol.1000548; pmid: 20921534
131. O. Neudorfer et al., Occurrence of Parkinson's syndrome in type I Gaucher disease. Q. J. Med. 89, 691-694 (1996). doi: 10.1093/qjmed/89.9.691; pmid: 8917744
132. W. Satake et al., Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307 (2009). doi: 10.1038/ng.485; pmid: 19915576
133. J. Simón-Sánchez et al., Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312 (2009). doi: 10.1038/ng.487; pmid: 19915575
134. C. Münch, J. O'Brien, A. Bertolotti, Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl. Acad. Sci. U.S.A. 108, 3548-3553 (2011). doi: 10.1073/pnas.1017275108; pmid: 21321227
135. T. Nonaka et al., Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Reports 4, 124-134 (2013). doi: 10.1016/j.celrep.2013.06.007;pmid:23831027
136. J. Brettschneider et al., Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 74, 20-38 (2013). doi: 10.1002/ana.23937; pmid: 23686809
137. D. B. Berry et al., Drug resistance confounding prion therapeutics. Proc. Natl. Acad. Sci. U.S.A. 110, E4160-E4169 (2013). doi: 10.1073/pnas.1317164110; pmid: 24128760
138. R. A. Crowther, M. Goedert, C. M. Wischik, The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease. Ann. Med. 21, 127-132 (1989). doi: 10.3109/07853898909149199; pmid: 2504257
139. M. G. Spillantini et al., Alpha-synuclein in Lewy bodies. Nature 388, 839-840 (1997). doi: 10.1038/42166; pmid: 9278044